What's happened
Biogen’s tau-targeting drug diranersen has shown potential in reducing tau levels and slowing cognitive decline in a small subset of a 400-person study, prompting plans for a larger trial. The results, presented at the Alzheimer’s Association International Conference in London, are cautiously optimistic but require confirmation in bigger studies.
What's behind the headline?
Analysis
- Diranersen represents a shift from clearing amyloid to reducing tau production, potentially preserving brain function longer.
- The data come from a small subset of about 400 participants; results show slower cognitive decline in this group, but the overall trial did not meet its primary endpoint for higher-dose efficacy.
- Independent experts view the findings as promising yet preliminary, likely to reinvigorate interest in tau-targeting approaches while underscoring the need for larger, confirmatory trials.
- The delivery method may influence adherence and accessibility, raising questions about long-term safety and real-world impact if benefits are confirmed.
- If future trials validate benefit, this could alter the standard landscape of Alzheimer’s therapies alongside existing anti-amyloid drugs.
How we got here
New approaches to treating Alzheimer’s are emerging alongside amyloid-clearing therapies. Diranersen is an antisense oligonucleotide that lowers tau production by targeting a tau-producing gene, offering a different path to slowing disease progression. The delivery is intrathecal, delivering the drug directly to the brain via spinal fluid, which contrasts with bloodstream infusions used for current anti-amyloid drugs.
Our analysis
Independent reports from London conference, with cautious optimism from Jessica Langbaum and Reisa Sperling; AP News also covers Biogen’s findings, echoing similar cautious interpretations.
Go deeper
- How soon could a larger trial enroll participants and publish results?
- Will this lead to a shift in funding toward tau-targeting therapies?
- What are the potential risks or side effects of the intrathecal delivery method?
More on these topics
-
Biogen - Biotechnology company
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide.
-
lecanemab - Medication
Lecanemab, sold under the brand name Leqembi, is a monoclonal antibody medication used for the treatment of Alzheimer's disease. Lecanemab is an amyloid beta-directed antibody. It is given via intravenous infusion to patients with mild cognitive impairmen
-
University College London - Public university in London, England
University College London, officially known as UCL since 2005, is a public research university located in London, United Kingdom.
-
Tau - Protein
The tau proteins are a group of six highly soluble protein isoforms produced by alternative splicing from the gene MAPT. They have roles primarily in maintaining the stability of microtubules in axons and are abundant in the neurons of the central nervous
-
London - Capital and largest city of England and the United Kingdom
London is the capital and largest city of both England and the United Kingdom, with a population of 9.1 million people in 2024. Its wider metropolitan area is the largest in Western Europe, with a population of 15.1 million. London stands on the River...
-
donanemab - Drug
Donanemab is a biological drug in trial to treat early symptoms of Alzheimer's disease. There is no cure or treatment for Alzheimer’s disease. Donanemab has shown positive results in Eli Lilly and Co.’s first two trials.
-
Massachusetts - US State
Massachusetts, officially known as the Commonwealth of Massachusetts, is the most populous state in the New England region of the northeastern United States.